Profile

ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its platform has been validated (in-vivo and with unprecedented in-vitro characteristics) with three top 25 pharma companies in their experimental assays.

ProteinQure is the only computational platform capable of designing peptides with the full complement of non-canonical amino acids, so that its peptides are 100 time better than natural peptide ligands. For ProteinQure’s own internal programs, the company uses the novel peptides to help deliver payloads in a tissue-specific manner. Peptides are ideal for delivery of different payloads like radioisotopes and gene therapy since they are tissue-specific and easier to manufacture. ProteinQure’s lead program for Trodelvy-resistant triple-negative breast cancer (TNBC) has begun investigational new drug (IND)-enabling studies. ProteinQure also has an exciting in-vivo proof of concept (POC) for short interfering ribonucleic acid (siRNA) delivery to central nervous system (CNS).

ProteinQure Inc. logo

Website

proteinqure.com

Contact


Event details

Date: November 4 - 6, 2024

Event contact

Rita Patlan
Area Director
Europe: Aerospace and Defence, Environmental Technologies and Infrastructure

Participants

12 in total